



## Cancer Research

Latest Update 9/22/2025

### Cancer

- **NCI, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)** ([PAR-25-336](#)). **Expiration Date: November 16, 2027.**
- **NCI, Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)** ([PAR-25-106](#)). **Expiration Date: May 05, 2026.**
- **NCI, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)** ([PAR-25-175](#)). **Expiration Date: January 08, 2028.**
- **NCI, NIAAA, Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)** ([PAR-25-221](#)). **Expiration Date: January 08, 2027.**
- **NCI, Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)** ([PAR-25-167](#)). **Expiration Date: January 08, 2027.**
- **NCI, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)** ([PAR-24-304](#)). **Expiration Date: October 15, 2026.**
- **NCI, National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)** ([PAR-25-081](#)). **Expiration Date: January 08, 2027.**

- **NCI**, Modular R01s in Cancer Control and Population Sciences (**R01** Clinical Trial Optional) ([PA-25-172](#)). **Expiration Date: January 08, 2028.**
- **NCI**, Molecular Imaging of Inflammation in Cancer (**R01** Clinical Trial Not Allowed) ([PAR-24-311](#)). **Expiration Date: January 08, 2028.**
- **NCI**, Mechanisms that Impact Cancer Risk after Bariatric Surgery (**R01** Clinical Trial Optional) [PAR-25-043](#), (**R21** Clinical Trial Not Allowed) [PAR-25-044](#). **Expiration Date: January 08, 2028.**
- **NIH**, Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (**R01** Clinical Trial Not Allowed) ([PAR-25-095](#)); (**R21** Clinical Trials Not Allowed) ([PAR-25-096](#)). **Expiration Date: September 08, 2026.**
- **NCI**, Co-infection and Cancer (**R01** Clinical Trial Not Allowed) ([PAR-25-082](#)); (**R21** Clinical Trial Not Allowed) ([PAR-25-083](#)). **Expiration Date: January 08, 2026.**
- **NCI**, Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (**R01** Clinical Trial Optional) ([PAR-25-069](#)); (**R21** Clinical Trial Not Allowed) ([PAR-25-070](#)). **Expiration Date: January 08, 2027.**
- **NCI**, NCI Small Grants Program for Cancer Research (NCI Omnibus) (**R03** Clinical Trial Optional) ([PAR-25-078](#)). **Expiration Date: January 08, 2026.**
- **NCI**, Exploratory Grants in Cancer Control (**R21** Clinical Trial Optional) ([PA-25-253](#)). **Expiration Date: September 08, 2028.**
- **NCI**, Cancer Prevention and Control Clinical Trials Planning Grant Program (**U34** Clinical Trials Optional) ([PAR-25-103](#)); (**R34** Clinical Trials Optional) ([PAR-25-104](#)). **Expiration Date: October 26, 2027.**
- **NCI** Pathway to Independence Award (**K99/R00** Clinical Trial Not Allowed) ([PAR-25-135](#)). **Expiration Date: October 15, 2027.**
- **NCI**, Assay Validation of High Quality Markers for Clinical Studies in Cancer (**UH2/UH3** Clinical Trial Not Allowed) ([PAR-25-074](#)), (**UH3** Clinical Trials Not Allowed) ([PAR-25-075](#)). **Expiration Date: October 15, 2026.**

- **Louisiana Cancer Research Center (LCRC)** announce the opening of new Louisiana Cancer Research Center funding opportunities for the current cycle. Due **11/3/2025**. [Details](#).
  - o **Seed Grants** – These grants support early-stage, innovative projects with the potential to generate preliminary data and serve as a foundation for larger grant applications. Seed grants provide critical funding for high-risk, high-reward research aligned with LCRC’s mission and strategic priorities.
  - o **New Investigator Awards** – This program fosters the development of emerging faculty and researchers early in their careers. These awards support independent research projects and help recipients establish a track record of excellence in cancer research

•